| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000015096 |
| Receipt No. | R000017544 |
| Official scientific title of the study | Utility of contrast-enhanced harmonic endoscopic ultrasonography for diagnosis of liver metastases of the pancreatic carcinomas: a prospective cohort study |
| Date of disclosure of the study information | 2014/09/10 |
| Last modified on | 2017/02/10 (Ver. 4) |
| Basic information | ||
| Official scientific title of the study | Utility of contrast-enhanced harmonic endoscopic ultrasonography for diagnosis of
liver metastases of the pancreatic carcinomas: a prospective cohort study |
|
| Title of the study (Brief title) | Utility of contrast-enhanced harmonic endoscopic ultrasonography for diagnosis of
liver metastases of the pancreatic carcinomas: a prospective cohort study |
|
| Region |
|
|
| Condition | ||
| Condition | Pancreatic carcinomas | |
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | The aim of the present study is to evaluate the utility of contrast-enhanced harmonic EUS in diagnosis of liver metastases from pancreatic carcinomas, by comparing it with conventional EUS. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Phase IV |
| Assessment | |
| Primary outcomes | To calculate ability of contrast-enhanced harmonic EUS in diagnosing liver metastases from pancreatic carcinomas.
To compare the ability of contrast-enhanced harmonic EUS in diagnosing liver metastases from pancreatic carcinomas with that of conventinal EUS. |
| Key secondary outcomes | To compare the ability of contrast-enhanced harmonic EUS with those of MDCT, MRI and PET. |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Pancreatic carcinoma with confirmation by imaging and pathological examinations.
Written informed consent ECOG performance status = 0-2 |
|||
| Key exclusion criteria | Inapropriate to perform endoscopic ultrasonography
Failure of other organs (ASA: Grade 3, 4) Inability to obtain informed consent |
|||
| Target sample size | 200 | |||
| Research contact person | |
| Name of lead principal investigator | Masayuki Kitano |
| Organization | Kinki University Faculty of Medicine |
| Division name | Department of gastroenterology and Hepatology |
| Address | 377-2 Ohno-higashi, Osaka-sayama, Osaka |
| TEL | 072-366-0221 |
| m-kitano@med.kindai.ac.jp | |
| Public contact | |
| Name of contact person | Masayuki Kitano |
| Organization | Kinki University Faculty of Medicine |
| Division name | Department of Gastroenterology and Hepatology |
| Address | 377-2 Ohno-higashi, Osaka-sayama, Osaka |
| TEL | 072-366-0221 |
| Homepage URL | |
| m-kitano@med.kindai.ac.jp | |
| Sponsor | |
| Institute | Department of Gastroenterology and Hapatology, Kinki University Faculty of Medicine |
| Institute | |
| Department | |
| Funding Source | |
| Organization | the Japan Society for the Promotion of Science |
| Organization | |
| Division | |
| Category of Funding Organization | |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | Conventional EUS and contrast-enhanced harmonic EUS is performed in patients with pancreatic carcinomas. CT, MRI and PET are performed in all the same patients.
Diagnostic abilities to detect liver metastases for all imaging methods are evaluated. |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000017544 |